Need Help? Chat Now With a Live Representative!

CTO Hunter Walker Sits For A Video Interview with Veeva

CTO Hunter Walker Sits For A Video Interview with Veeva

CTO Hunter Walker Sits For A Video Interview with Veeva

February 20, 2019

Chief Technology Officer Hunter Walker sat for an interview to discuss the ARG-Veeva partnership in September, 2018. Filmed in Philadelphia, the recently-released final video is a customer story designed to highlight Hunter's thoughts about how ARG has evolved over time, and to outline the relationship shared by the two organizations.

Hunter addresses both by saying: "ARG’s vision really is to be the best rare disease CRO and to service our clients accordingly. We think Veeva will help us do that by gaining those efficiencies within the clinical trials landscape by integrating the different applications into a single suite."

Hunter also looks ahead by looking back, stating: "I believe, one of the things that’s changed the most at Atlantic Research Group in the last five years is the complexity of the clinical trials. That’s the one thing I’ve noticed and we’ve recognized pretty early that we needed to be nimble in our applications and our thinking and this is how these new technologies are helping us do that."

Please watch the video here:

Clinical Operations

Please read about ARG technology here.

Breaking Ground in Medicine: Our Role in the Approval of Bivigam by ADMA Biologics

Breaking Ground in Medicine: Our Role in the Approval of Bivigam by ADMA Biologics

Since 2004, ARG has been working in the immunology space, using our individualized approach to optimize the likelihood of successful […]

March 8, 2024
ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

ARG and Humacyte Collaborate on Human Acellular Vessel (HAV) Program Advancements in Vascular Trauma

CHARLOTTESVILLE, VIRGINIA – ARG (Atlantic Research Group) proudly announces its ongoing collaboration with Humacyte, a leading biotechnology company, on the […]

February 23, 2024
Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

Revolutionizing Treatment: Our Contribution to Humacyte’s Latest Innovation

In 2014, ARG began working with Humacyte on their Human Acellular Vessel (HAV) interposition graft program, which included three separate […]

February 7, 2024
GO TO TOP